title: [Natalizumab (Tysabri)].
abstract: Natalizumab is a humanized recombinant monoclonal antibody against alpha4-intigrin. In a large phase III study on relapsing-remitting MS Natalizumab reduced the relapse rate by 68% and the appearance of permanent neurological deficits by 42%. Currently, Natalizumab is the most effective disease-modifying treatment of relapsing-remitting MS. The clinical use of the treatment will be restricted initially due to uncertainty about the risk of opportunistic infections in long term treatment.
authors.affiliation: Rigshospitalet, Neurocentret, Dansk Multipel Sklerose Center, København Ø. mads.ravnborg@rh.hosp.dk
authors.forename: Mads
authors.initials: M
authors.lastname: Ravnborg
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab